Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(10%)
Results Posted
100%(5 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_3
3
30%
Ph not_applicable
3
30%
Ph phase_4
1
10%
Ph phase_1
1
10%
Ph phase_2
2
20%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)
Other(3)

Detailed Status

Completed5
unknown3
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
1
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 22 (20.0%)
Phase 33 (30.0%)
Phase 41 (10.0%)
N/A3 (30.0%)

Trials by Status

active_not_recruiting110%
completed550%
terminated110%
unknown330%

Recent Activity

1 active trials
Showing 5 of 10
active_not_recruitingphase_1

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
unknownnot_applicable

Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children

NCT05315024
unknownphase_2

Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen

NCT05028322
terminatedphase_2

Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients

NCT00596336
completednot_applicable

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

NCT00707174
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT03872947Phase 1

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Active Not Recruiting
NCT05315024Not Applicable

Influenza Vaccine With Topical Imiquimod in Influenza Vaccine Non-responsive Children

Unknown
NCT05028322Phase 2

Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen

Unknown
NCT00596336Phase 2

Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients

Terminated
NCT00707174Not Applicable

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

Completed
NCT00894647Phase 3

Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery

Completed
NCT00116649Phase 4

Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis

Completed
NCT00605176Phase 3

Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)

Completed
NCT00603798Phase 3

Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)

Completed
NCT00463359Not Applicable

A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10